Xenetic Biosciences, Inc. (XBIO) Stock

Xenetic Biosciences, Inc. (XBIO) is a Healthcare stock trading at $3.59 (as of 2026-08-21), with a market capitalization of $8.22M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Understand Xenetic Biosciences, Inc.: how it makes money

Xenetic Biosciences develops personalized CAR T cell therapies and related biologic oncology therapeutics through discovery and research and development, advancing its XCART platform to target patient specific tumor neoantigens and leveraging its PolyXen drug delivery platform via biotechnology partnerships.

Because Xenetic Biosciences is building a personalized cell therapy platform (XCART) and related delivery technology (PolyXen) through discovery and research and development, its profitability is structurally tied to whether those programs can progress and ultimately generate value through continued development and partnering rather than to current product revenue.

Business quality (Weak): Key disclosures needed for a retail investor panel are missing here, specifically official reportable segments and operational KPIs, and the latest quarter shows 0.0B revenue and a -62.2 operating margin, so the near term picture is loss driven with limited operating metrics to track.

Bull case

Personalized CAR T platform focus: XCART is designed to target patient specific tumor neoantigens, and the company is advancing cell based therapeutics for B cell lymphomas via targeting the B cell receptor on malignant tumor cells.
Platform approach with delivery technology: The company also leverages PolyXen, its proprietary drug delivery platform, including through biotechnology partnerships.

Bear case

Loss making profile in the latest period: For the period 2026-03-31, operating margin is -62.2, which indicates the company is not yet converting its R and D efforts into operating profitability.
Limited transparency on operating drivers: No operational KPIs or official reportable segments were provided here, which makes it harder to track day to day business momentum versus program level outcomes.

Valuation — source: SEC EDGAR (first-party)
Price	$3.59
Market Cap	$8.22M
Price / Book	1.35
Price / Sales	2.52

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.98M
Net Margin	-90.1%
Revenue Growth (YoY)	12.0%
EPS Growth (YoY)	-8.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-28.11 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RENAISSANCE TECHNOLOGIES LLC ($368339.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	James F. Parslow
Employees	2
Country	US
IPO Date	2016-06-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.